Displaying 29 (all) recruiting clinical trials.
-
AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to ... -
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
The purpose of this study is to test the safety, tolerability, and effectiveness of MRTX849 (called “the study drug” from now on) for advanced cancers ... -
A Phase 1/2 Open-Label Multi-Center First-in-Human Study of the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK ROS1 or NTRK1-3 Rearrangements (TRIDENT-1)
The purpose of this Phase 1/2 research study is to test the effects of an investigational study drug called repotrectinib for the possible treatment ... -
First-in-human open-label dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors
The purpose of the study is to determine the safety of GEN1046 in patients with malignant solid tumors. GEN1046 is investigational drug in this study ... -
A Phase 1/2a Open-Label Multi-Center Trial to Assess Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of CLN-081 in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
The purpose of the study is to look at safety and tolerability of orally administered CLN-081 monotherapy, as single dose and after multiple doses over ... -
A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
The purpose of the study is to determine if M3814 in combination with radiation therapy and avelumab is safe and tolerable in patients with advanced ... -
An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome
The purpose of this study is to see how safe and effective a drug called STK-001 is for people with Dravet syndrome. This is an ... -
A Phase 1/2 First-in-Human Open-Label Dose Escalation Study of Talquetamab a Humanized GPRC5D x CD3 Bispecific Antibody in Subjects with Relapsed or Refractory Multiple Myeloma
The purpose of the study is to determine if talquetamab is safe and useful for treating patients with multiple myeloma and to assess how the ... -
An Open-Label Multicenter Non-Randomized Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety Tolerability and Anti-Tumor Activity of ATP128 With or Without BI 754091 in Patients With Stage IV Colorectal Cancer
The purpose of the study is to determine the safety and tolerability of ATP128 alone or in combination with BI 754091. ATP128 is a self-adjuvanted ... -
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
The purpose of the study is to determine the efficacy of investigational agents with or without pembrolizumab for the treatment of PD-1 naïve or PD-1 ...